Dr Adam Bryant

Back to

Adam is a Senior Staff Specialist Haematologist at Liverpool Hospital in South Western Sydney (SWS) and a Conjoint Senior Lecturer with the University of New South Wales. He is the current President and NSW Councillor of the Haematology Society of Australia and New Zealand.

At Liverpool Hospital, Adam leads the Myeloma and Plasma Cell Disorders Unit and serves as Deputy Director of the Transplant and Cellular Therapies Unit, where he is overseeing the development of the hospital’s standard-of-care CAR-T cell program for myeloma.

Through the SWS Local Health District’s Haematology Clinical Research Unit, Adam has been Principal Investigator for numerous myeloma clinical trials, both industry-sponsored and collaborative. He is also a member of the Myeloma Working Party of the Australasian Leukaemia and Lymphoma Group and the Medical and Scientific Advisory Group (MSAG) of Myeloma Australia.

Phone

02 8738 5167

E-mail

LiverpoolHaematologyConsulting@health.nsw.gov.au

Location

Liverpool Hospital

Book Chapters | 2021

Bryant A, 2021, 'Elotuzumab', in Resistance to Targeted Anti-Cancer Therapeutics, Springer International Publishing, pp. 73 - 82, http://dx.doi.org/10.1007/978-3-030-73440-4_6

Book Chapters | 2017

Bryant A; Atkins H, 2017, 'Autoimmune disorders', in Clinical Manual of Blood and Bone Marrow Transplantation, pp. 221 - 228, http://dx.doi.org/10.1002/9781119095491.ch25
Journal articles | 2026

Kurniawan S; Hwang A; Doo NW; King T; Bryant C; Zhang J; Whelan K; Fani-Molky P; Kidson-Gerber G; Bosco A; Hamad N; Parmar G; Kwok F; Lai S; Ling S; Ho PJ; McCaughan G; Bryant A, 2026, 'Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant-Ineligible Newly Diagnosed Myeloma: An Australian Real-World, Multicenter Study', Asia Pacific Journal of Clinical Oncology, http://dx.doi.org/10.1111/ajco.70101

Journal articles | 2026

Kwan G; Kwan T; Fernando S; Lee F; Lin M; Yun J; Bryant A; Ling S; Toong C, 2026, 'Comparative performance of Freelite and N-Latex serum free light chain assays across a multicentre New South Wales cohort', Pathology, 58, pp. S67 - S67, http://dx.doi.org/10.1016/j.pathol.2026.01.293

Journal articles | 2026

Zhong S; Ashraf MA; Dhir V; Matta L; Bryant A; McEwan A; Watson A-M; Hua M; Ng S; Hsu D; Dunlop L; Hsu H; Sungala N; Motum P; Beaton B, 2026, 'Duffy-null-associated absolute neutrophil count (DANC): an audit from south-western Sydney evaluating the neutrophil lower reference range for patients with DANC', Pathology, 58, pp. S64 - S64, http://dx.doi.org/10.1016/j.pathol.2026.01.282

Journal articles | 2025

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; Almeida ACD; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Lacerda MPD; Garcia EG; Balarí AS; Kazeem B; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Robak P; Mateos M-V, 2025, 'MM-1049: DREAMM-7 Study of Belantamab Mafodotin + Bortezomib + Dexamethasone vs Daratumumab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', Clinical Lymphoma Myeloma and Leukemia, 25, pp. S960 - S960, http://dx.doi.org/10.1016/s2152-2650(25)02676-x

Journal articles | 2025

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; Almeida ACD; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Lacerda MPD; Garcia EG; Balarí AS; Kazeem B; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Robak P; Mateos M-V, 2025, 'POSTER: MM-1049 DREAMM-7 Study of BelantamabMafodotin + Bortezomib + Dexamethasone vs Daratumumab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', Clinical Lymphoma Myeloma and Leukemia, 25, pp. S306 - S306, http://dx.doi.org/10.1016/s2152-2650(25)01319-9

Journal articles | 2025

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; de Almeida AC; Hájek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Garcia EG; Balarí AS; Kazeem B; Pirooz N; Varghese S; Lee J; Baig H; Eccersley L; Robak P; Mateos M-V, 2025, 'DREAMM-7 Study of Belantamab Mafodotin + Bortezomib (V) + Dexamethasone (d) vs Daratumumab + Vd in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', Clinical Lymphoma Myeloma and Leukemia, 25, pp. S321 - S322, http://dx.doi.org/10.1016/s2152-2650(25)03938-2

Journal articles | 2025

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Pitombeira de Lacerda M; Martinez G; Sureda Balarí A; Mielnik M; Nichols M; Mouro J; Khalaf Z; Baig H; Polinkovsky M; Pirooz N; Varghese S; Lee J; Eccersley L; Mateos M-V, 2025, 'Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma', Blood, 146, pp. 2262 - 2262, http://dx.doi.org/10.1182/blood-2025-2262

Journal articles | 2025

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hájek R; Kim K; Grosicki S; Sia H; Bryant A; Pitombeira de Lacerda M; Martinez GA; Sureda Balarí A; Sandhu I; Cerchione C; Ganly P; Dimopoulos MA; Fu C; Garg M; Abdallah AO; Gatt ME; Oriol Rocafiguera A; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Ficek J; Mantero A; Pirooz N; Varghese S; Lee J; McKeown A; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Mukhopadhyay P; Nielsen J; Opalinska J; Mateos MV, 2025, 'Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial', Lancet Oncology, 26, pp. 1067 - 1080, http://dx.doi.org/10.1016/S1470-2045(25)00330-4

Journal articles | 2025

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; de Almeida AC; Hájek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Aparecida-Martinez G; Balarí AS; Kazeem B; Lin CP; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Khalaf Z; Mateos M-V, 2025, 'Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V), and Dexamethasone (d) vs Daratumumab-Vd in RRMM', Clinical Lymphoma Myeloma and Leukemia, 25, pp. S333 - S334, http://dx.doi.org/10.1016/s2152-2650(25)03957-6

Journal articles | 2025

Owen R; Bryant A; Finch L; Franklin D; Abdollahi M; Abolhasan M, 2025, 'Failures and Resilience in the IP Era: Navigating the Fragility of Modern Telecommunications Networks-The Sovereign Functions', IEEE ACCESS, 13, pp. 155759 - 155777, http://dx.doi.org/10.1109/ACCESS.2025.3602054

Journal articles | 2025

Sim S; Bryant A; Forsyth C; Motorna O; Brotchie J; Hocking J; Yong A; Chien N; Kerridge I; Lai HC; Solterbeck A; Traficante R; Jocic M; Quach H, 2025, 'Interim analysis of efficacy and safety for ALLG MM25 (Viber-M): A phase I b/II study of venetoclax, iberdomide and dexamethasone for patients in first or second relapse of multiple myeloma with t(11;14)', Blood, 146, pp. 249 - 249, http://dx.doi.org/10.1182/blood-2025-249

Journal articles | 2024

Al‐Ammari M; Hsu D; Bryant A, 2024, 'Myeloma‐associated hemophagocytic lymphohistiocytosis – A comprehensive case study and a novel chemotherapy‐free approach with anakinra', eJHaem, 5, pp. 1057 - 1062, http://dx.doi.org/10.1002/jha2.975

Journal articles | 2024

Bryant A; Quach H, 2024, 'Biomarker-directed therapy in multiple myeloma', Current Opinion in Oncology, 36, pp. 600 - 609, http://dx.doi.org/10.1097/CCO.0000000000001091

Journal articles | 2024

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Ribas de Almeida AC; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Pitombeira de Lacerda M; Martinez GA; Balarí AMS; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah AO; Oriol A; Gatt ME; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; McKeown A; McNamara S; Zhou X; Nichols M; Lewis E; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos MV, 2024, 'Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma', New England Journal of Medicine, 391, pp. 393 - 407, http://dx.doi.org/10.1056/NEJMoa2405090

Journal articles | 2024

Li EW; Jones E; Bryant C; King T; Talaulikar D; Ng JY; Bryant A; Ridha Z; Doo NW; Menzies A; Ling S; Ho SJ; Abadir E; Vanguru V; Joshua D; Ho PJ, 2024, 'A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies', European Journal of Haematology, 113, pp. 521 - 529, http://dx.doi.org/10.1111/ejh.14266

Journal articles | 2024

Lim KJC; Wellard C; Moore E; Gration B; Augustson B; Mollee P; Zhang J; Doo NW; Ringkowski S; Bryant A; Ninkovic S; Hamad N; Mccaughan G; Kumar S; Spencer A; Quach H, 2024, 'Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry', BLOOD, 144, pp. 1951 - 1952, http://dx.doi.org/10.1182/blood-2024-207609

Journal articles | 2024

Tong MH; Kwok A; Walsh A; Heydon P; Koh ES; McNamara N; Bryant A, 2024, 'Isolated Ocular Relapse of Acute Myeloid Leukaemia Post Allogeneic Stem Cell Transplant', Case Reports in Ophthalmological Medicine, 2024, pp. 2235819, http://dx.doi.org/10.1155/2024/2235819

Journal articles | 2023

Li E; Bryant C; Jones E; King T; Talaulikar D; Ng J; Bryant A; Ridha Z; Doo NW; Ling S; Ho PJ; Joshua D, 2023, 'P-289 The efficacy and safety of prednisone, cyclophosphamide, doxorubicin and carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy', Clinical Lymphoma Myeloma and Leukemia, 23, pp. S196 - S196, http://dx.doi.org/10.1016/s2152-2650(23)01907-9

Journal articles | 2023

Plesner T; Harrison SJ; Quach H; Lee C; Bryant A; Vangsted A; Estell J; Delforge M; Offner F; Twomey P; Choeurng V; Li J; Hendricks R; Ruppert SM; Sumiyoshi T; Miller K; Cho E; Schjesvold F, 2023, 'Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma', Clinical Hematology International, 5, pp. 43 - 51, http://dx.doi.org/10.1007/s44228-022-00023-5

Journal articles | 2023

Ponraj R; Bryant A; Dunlop L; Range H; Cobrador C; Ling S; Hsu D, 2023, 'Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA', Blood Cancer Journal, 13, pp. 113, http://dx.doi.org/10.1038/s41408-023-00885-9

Journal articles | 2021

McCaughan GJ; Verma A; Ling S; Lavee O; Moore JJ; Bryant A, 2021, 'Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres', Bone Marrow Transplantation, 56, pp. 738 - 740, http://dx.doi.org/10.1038/s41409-020-01086-9

Journal articles | 2020

Keane C; Fearnhead NS; Bordeianou LG; Christensen P; Espin Basany E; Laurberg S; Mellgren A; Messick C; Orangio GR; Verjee A; Wing K; Bissett IP; An V; Bryant A; Byrne C; Chen T; Croft S; Clark D; Gladman M; Heriot A; Kariappa S; Keck J; Lubowski D; Dinning P; Khera A; Kirkwood K; Petersen D; Sloots K; Totten B; Weston M; Andersen P; Bachmann C; Barht H; Emmertsen K; Faaborg P; Gögenur I; Ingerslev P; Isaksen D; Iversen H; Iversen L; Jacobsen K; Jansen T; Jocobsen I; Juul T; Kjær D; Krogh K; Majgaard M; Mynster A; Neuenschwander A; Nielsen C; Nielsen R; Nielsen M; Nielsen T; Olsen J; Poulsen B; Rahr H; Snedker B; Sørensen G; Stolzenburg T; Vaabengaard P; Acheson A; Andreyev J; Bach S; Battersby N; Bradbury J; Brown S; Cecil T; Chapman S; Chapman M; Chave H; Cook T; Cuffy L; Davies J; Dawson C; Dixon J; Duff S; Edwards C; Geh I; Hamilton C; Hancock L; Harji D; Hill J; Holtham S; Jenkins J; Johnston R; Kapur S; Maxwell-Armstrong C; McArthur D; Moran B; Norton C; Nugent K; Pateman L; Perston Y; Rockall T; Sagar P; Saunders M; Sebag-Montefiore D; Senapati A; Singh B; Skaife P, 2020, 'International consensus definition of low anterior resection syndrome', ANZ Journal of Surgery, 90, pp. 300 - 307, http://dx.doi.org/10.1111/ans.15421

Journal articles | 2020

Othman J; Greenwood M; Moore J; Larsen S; Watson AM; Arthur C; Bhattacharyya A; Bilmon I; Blyth E; Bryant A; Bryant C; Dunlop L; Fay K; Gibson J; Hamad N; Kerridge I; Kwan J; Ma D; Micklethwaite K; Milliken S; Panicker S; Stevenson W; Withers B; Wilcox L; Tran S; Gottlieb DJ, 2020, 'Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG', Biology of Blood and Marrow Transplantation, 26, pp. 1868 - 1875, http://dx.doi.org/10.1016/j.bbmt.2020.06.030

Journal articles | 2019

Heelan F; Mallick R; Bryant A; Atkins H; Huebsch L; Bredeson C; Allan D; Kekre N, 2019, 'Comparison of Weight-Based and Lymphocyte Count-Based Dosing of Anti- Thymocyte Globulin in Matched Unrelated Donor Stem Cell Transplantation', Transplantation and Cellular Therapy, 25, pp. s236, http://dx.doi.org/10.1016/j.bbmt.2018.12.229

Journal articles | 2017

Bryant A; Mallick R; Huebsch LB; Allan DS; Atkins H; Anstee G; Bence-Bruckler I; Hamelin L; Hodgins M; Sabloff M; Scrivens N; Maze D; Bredeson CN; Kekre N, 2017, 'Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant', Biology of Blood and Marrow Transplantation, 23, pp. S360 - S361, http://dx.doi.org/10.1016/j.bbmt.2016.12.307

Journal articles | 2017

Grieco A; Doubova M; Bryant A; Mallick R; Aw A; Bredeson CN; Huebsch LB; Kekre N, 2017, '439 Does Having CLL Confer a Greater Risk of Graft Versus Host Disease in Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation?', Transplantation and Cellular Therapy, 23, pp. s368, http://dx.doi.org/10.1016/j.bbmt.2016.12.318

Journal articles | 2016

Bryant A; Mallick R; Huebsch LB; Allan DS; Atkins H; Anstee G; Bence-Bruckler I; Hamelin L; Hodgins M; Sabloff M; Scrivens N; Maze DC; Bredeson CN; Kekre N, 2016, 'Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant', Blood, 128, pp. 5782 - 5782, http://dx.doi.org/10.1182/blood.v128.22.5782.5782

Journal articles | 2014

Bilmon I; Nivison-Smith I; Hertzberg M; Ritchie D; Greenwood M; Spencer A; Kennedy G; Bryant A; Moore J, 2014, 'Outcomes following second allogeneic haematopoietic transplants using fludarabine–melphalan conditioning', Bone Marrow Transplantation, 49, pp. 852 - 853, http://dx.doi.org/10.1038/bmt.2014.23

Journal articles | 2014

Bryant A; Nivison-Smith I; Pillai ES; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil S; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearing R; Moore J, 2014, 'Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients', Bone Marrow Transplantation, 49, pp. 17 - 23, http://dx.doi.org/10.1038/bmt.2013.142

Journal articles | 2014

Bryant A; Pringle E; Bredeson C; Allan DS; Anstee G; Bence-Bruckler I; Hamelin L; Hopkins HS; Huebsch LB; Sabloff M; Sheppard DC; Tay J; Atkins H, 2014, 'Autologous Stem Cell Transplant for Myasthenia Gravis: A Single-Centre Experience', Blood, 124, pp. 3996, http://dx.doi.org/10.1182/blood.v124.21.3996.3996

Journal articles | 2014

Dalal BI; Al Mugairi A; Pi S; Lee SY; Khare NS; Pal J; Bryant A; Vakil AP; Lau S; Abou Mourad YR, 2014, 'Aberrant Expression of CD13 Identifies a Subgroup of Standard-Risk Adult Acute Lymphoblastic Leukemia With Inferior Survival', CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 14, pp. 239 - 244, http://dx.doi.org/10.1016/j.clml.2013.10.003

Journal articles | 2014

Palma CA; Al Sheikha D; Lim TK; Bryant A; Vu TT; Jayaswal V; Ma DDF, 2014, 'MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia', Molecular Cancer, 13, http://dx.doi.org/10.1186/1476-4598-13-79

Journal articles | 2012

Bryant A; Palma CA; Jayaswal V; Yang YH; Lutherborrow MA; Ma DD, 2012, 'miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death', Molecular Cancer, 11, pp. 8, http://dx.doi.org/10.1186/1476-4598-11-8

Journal articles | 2012

Bryant A; Sheppard D; Bredeson C; Sabloff M, 2012, 'Utility of Pre-Induction Cardiac Function Testing in Patients with Newly Diagnosed AML', Blood, 120, pp. 2068, http://dx.doi.org/10.1182/blood.v120.21.2068.2068

Journal articles | 2011

Bryant AJ; Palma CA; Lutherborrow M; Jayaswal V; Yang YH; Ma D, 2011, 'Knockdown of MicroRNA-10a in Acute Myeloid Leukaemia Cells Bearing the Nucleophosmin1 Mutation Causes Cell Death and Reduced Clonogenicity', Blood, 118, pp. 1367 - 1367, http://dx.doi.org/10.1182/blood.v118.21.1367.1367

Journal articles | 2011

Bryant AJ; Pillai E; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil SS; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearling R; Nivison-Smith I; Moore J, 2011, 'A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998–2008,', Blood, 118, pp. 4143 - 4143, http://dx.doi.org/10.1182/blood.v118.21.4143.4143

Journal articles | 2011

Loi TH; Campain A; Bryant AJ; Molloy T; Lutherborrow MA; Turner J; Yang YH; Ma DD, 2011, 'Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profiling', BMC Medical Genomics, 4, pp. 1 - 10, http://www.biomedcentral.com/1755-8794/4/27

Journal articles | 2011

Lutherborrow MA; Bryant AJ; Jayaswal V; Agapiou DJ; Palma CA; Yang YH; Ma DD, 2011, 'Expression profiling of cytogenetically normal acute myeloid leukemia identifies MicroRNAs that target genes involved in monocytic differentiation', American Journal of Hematology, 86, pp. 2 - 11, http://dx.doi.org/10.1002/ajh.21864

Journal articles | 2011

Palma CA; Tonna E; Bryant AJ; Jayaswal V; Agapiou D; Yang YH; Ma D; Lutherborrow M, 2011, 'MicroRNA Expression in Acute Myeloid Leukaemia and Their Effects on the Differentiation of Acute Myeloid Leukaemia Cells', Blood, 118, pp. 2430 - 2430, http://dx.doi.org/10.1182/blood.v118.21.2430.2430

Journal articles | 2010

Sasson SC; Smith S; Seddiki N; Zaunders J; Bryant AJ; Koelsch KK; Weatherall CJ; Munier CM; McGinley C; Yeung J; Mulligan S; Moore JJ; Cooper DA; Milliken ST; Kelleher AD, 2010, 'IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers', Cytokine, 50, pp. 58 - 68

Journal articles | 2009

Bryant A; Lutherborrow MA; Ma DD, 2009, 'The clinicopathological relevance of microRNA in normal and malignant haematopoiesis', Pathology, 41, pp. 204 - 213

Journal articles | 2008

Bryant A; Low J; Austin SA; Joseph JE, 2008, 'Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T`s score and particle gel immunoassay', British Journal of Haematology, 143, pp. 721 - 726

Journal articles | 2008

Bryant A; Milliken ST, 2008, 'Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma', Biology of Blood and Marrow Transplantation, 14, pp. 601 - 602, http://dx.doi.org/10.1016/j.bbmt.2008.01.010

Journal articles | 2006

Bryant A; Moore J, 2006, 'Rituximab and its potential for the treatment of rheumatoid arthritis', Therapeutics and Clinical Risk Management, 2, pp. 207 - 212, http://dx.doi.org/10.2147/tcrm.2006.2.2.207

Journal articles | 2006

Bryant A; Moore J, 2006, 'Rituximab and its potential for the treatment of rheumatoid arthritis', Therapeutics and Clinical Risk Management, 2, pp. 207 - 212, http://dx.doi.org/10.2147/tcrm.s22207
Conference Abstracts | 2026

Kwan G; Kwan T; Fernando S; Lee F; Lin M; Yun J; Bryant A; Ling S; Toong C, 2026, 'Comparative performance of Freelite and N-Latex serum free light chain assays across a multicentre New South Wales cohort', in Pathology, Elsevier BV, Vol. 58, pp. S67 - S67, http://dx.doi.org/10.1016/j.pathol.2026.01.293

Conference Abstracts | 2026

Zhong S; Ashraf MA; Dhir V; Matta L; Bryant A; McEwan A; Watson A-M; Hua M; Ng S; Hsu D; Dunlop L; Hsu H; Sungala N; Motum P; Beaton B, 2026, 'Duffy-null-associated absolute neutrophil count (DANC): an audit from south-western Sydney evaluating the neutrophil lower reference range for patients with DANC', in Pathology, Elsevier BV, Vol. 58, pp. S64 - S64, http://dx.doi.org/10.1016/j.pathol.2026.01.282

Conference Papers | 2025

Bryant A; Owen R; Silleri K, 2025, 'From Outage to Opportunity: Building Robust Telecommunications Standards for Emergency Services', in 2025 INTERNATIONAL WIRELESS COMMUNICATIONS AND MOBILE COMPUTING, IWCMC, IEEE, U ARAB EMIRATES, Abu Dhabi, pp. 1288 - 1293, presented at 21st International Wireless Communications and Mobile Computing-IWCMC-Annual, U ARAB EMIRATES, Abu Dhabi, 12 May 2025 - 16 May 2025, http://dx.doi.org/10.1109/IWCMC65282.2025.11059627

Conference Abstracts | 2025

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; Almeida ACD; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Lacerda MPD; Garcia EG; Balari AS; Kazeem B; Pirooz N; Lee J; Baig H; Eccersley L; Robak P; Mateos M-V; Varghese S, 2025, 'DREAMM-7 Study of Belantamab Mafodotin plus Bortezomib (V) plus Dexamethasone (d) vs Daratumumab plus Vd in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, CIG MEDIA GROUP, LP, Vol. 25

Conference Abstracts | 2025

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; Almeida ACD; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Lacerda MPD; Garcia EG; Balarí AS; Kazeem B; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Robak P; Mateos M-V, 2025, 'POSTER: MM-1049 DREAMM-7 Study of BelantamabMafodotin + Bortezomib + Dexamethasone vs Daratumumab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', in Clinical Lymphoma Myeloma and Leukemia, Elsevier BV, Vol. 25, pp. S306 - S306, http://dx.doi.org/10.1016/s2152-2650(25)01319-9

Conference Abstracts | 2025

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; Almeida ACD; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Garcia EG; Balari AS; Kazeem B; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Robak P; Mateos V, 2025, 'DREAMM-7 Study of Belantamab Mafodotin plus Bortezomib plus Dexamethasone vs Daratumumab plus Bortezomib plus Dexamethasone in Relapsed/ Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, CIG MEDIA GROUP, LP, Vol. 25

Conference Abstracts | 2025

Hungria V; Hus M; Zherebtsova V; Ward C; Ho PJ; de Almeida AC; Hájek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Garcia EG; Balarí AS; Kazeem B; Pirooz N; Varghese S; Lee J; Baig H; Eccersley L; Robak P; Mateos M-V, 2025, 'DREAMM-7 Study of Belantamab Mafodotin + Bortezomib (V) + Dexamethasone (d) vs Daratumumab + Vd in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy', in Clinical Lymphoma Myeloma and Leukemia, Elsevier BV, Vol. 25, pp. S321 - S322, http://dx.doi.org/10.1016/s2152-2650(25)03938-2

Conference Abstracts | 2025

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Lacerda MPD; Martinez GA; Balari AMS; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah A-O; Gatt ME; Oriol A; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; Lee J; Mckeown A; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Mateos MV, 2025, 'Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial', in BLOOD, ELSEVIER, FL, Orlando, Vol. 144, pp. 772 - 774, presented at 66th Annual Meeting of the American-Society-of-Hematology (ASH), FL, Orlando, 06 December 2025 - 09 December 2025, http://dx.doi.org/10.1182/blood-2024-200336

Conference Abstracts | 2025

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Martinez G; Balari AS; Mielnik M; Nichols M; Mouro J; Khalaf Z; Baig H; Polinkovsky M; Pirooz N; Varghese S; Lee J; Eccersley L; Mateos M-V, 2025, 'Long-term responders from the Phase 3 dreamm-7 study of belantamab mafodotin plus bortezomib and dexamethasone vs daratumumab plus bortezomib and dexamethasone in Relapsed/Refractory multiple myeloma', in BLOOD, ELSEVIER, FL, Orlando, Vol. 146, pp. 2262 - 2263, presented at 67th Annual Meeting of the American-Society-of-Hematology (ASH), FL, Orlando, 06 December 2025 - 09 December 2025, http://dx.doi.org/10.1182/blood-2025-2262

Conference Abstracts | 2025

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; de Almeida AC; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Aparecida-Martinez G; Balari AS; Kazeem B; Lin CP; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Khalaf Z; Mateos M-V, 2025, 'Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V) and Dexamethasone (d) vs Daratumumab-Vd in RRMM', in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, CIG MEDIA GROUP, LP, Vol. 25

Conference Abstracts | 2025

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; de Almeida AC; Hájek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda MP; Aparecida-Martinez G; Balarí AS; Kazeem B; Lin CP; Baig H; Pirooz N; Varghese S; Lee J; Eccersley L; Khalaf Z; Mateos M-V, 2025, 'Outcomes in Second-Line Lenalidomide-Refractory Patients in the Phase 3 DREAMM-7 Study of Belantamab Mafodotin, Bortezomib (V), and Dexamethasone (d) vs Daratumumab-Vd in RRMM', in Clinical Lymphoma Myeloma and Leukemia, Elsevier BV, Vol. 25, pp. S333 - S334, http://dx.doi.org/10.1016/s2152-2650(25)03957-6

Conference Abstracts | 2025

Khalaf Z; Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho P; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; de Lacerda M; Martinez G; Balari A; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah A-O; Gatt M; Oriol A; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; Lee J; McKeown A; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos M, 2025, 'Belantamab Mafodotin plus Bortezomib plus Dexamethasone vs Daratumumab plus Vd in RRMM: Updates on Overall Survival and Efficacy in DREAMM-7', in BRITISH JOURNAL OF HAEMATOLOGY, WILEY, SCOTLAND, Glasgow, Vol. 206, presented at 65th Annual Scientific Meeting of the British-Society-for-Haematology, SCOTLAND, Glasgow, 27 April 2025 - 29 April 2025

Conference Abstracts | 2025

Lim KJC; Wellard C; Moore E; Gration B; Augustson B; Mollee P; Zhang J; Doo NW; Ringkowski S; Bryant A; Ninkovic S; Hamad N; Mccaughan G; Kumar S; Spencer A; Quach H, 2025, 'Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry', in BLOOD, ELSEVIER, FL, Orlando, Vol. 144, pp. 1951 - 1952, presented at 66th Annual Meeting of the American-Society-of-Hematology (ASH), FL, Orlando, 06 December 2025 - 09 December 2025, http://dx.doi.org/10.1182/blood-2024-207609

Conference Abstracts | 2025

Sim S; Bryant A; Forsyth C; Motorna O; Brotchie J; Hocking J; Yong A; Chien N; Kerridge I; Lai HC; Solterbeck A; Traficante R; Jocic M; Quach H, 2025, 'The 67th ASH Annual Meeting Abstracts ORAL', in BLOOD, ELSEVIER, FL, Orlando, Vol. 146, pp. 249 - 250, presented at 67th Annual Meeting of the American-Society-of-Hematology (ASH), FL, Orlando, 06 December 2025 - 09 December 2025, http://dx.doi.org/10.1182/blood-2025-249

Conference Papers | 2023

Bryant C; Abadir E; Doo NW; Bryant A; McCaughan G; Yang S; Vanguru V; King T; Joshua D; Ho PJ, 2023, 'Failure to clear circulating tumor cells after one week of daratumumab, bortezomib and dexamethasone is associated with a reduced progression-free survival for myeloma patients', in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, CIG MEDIA GROUP, LP, pp. S73 - S73

Conference Abstracts | 2023

Bryant C; Abadir E; Doo NW; Bryant A; McCaughan G; Yang S; Vanguru V; King T; Joshua D; Ho PJ, 2023, 'P-070 Failure to clear circulating tumor cells after one week of daratumumab, bortezomib and dexamethasone is associated with a reduced progression-free survival for myeloma patients', in Clinical Lymphoma Myeloma and Leukemia, Elsevier BV, Vol. 23, pp. S73 - S73, http://dx.doi.org/10.1016/s2152-2650(23)01688-9

Conference Abstracts | 2023

Li E; Bryant C; Jones E; King T; Talaulikar D; Ng J; Bryant A; Ridha Z; Doo NW; Ling S; Ho PJ; Joshua D, 2023, 'P-289 The efficacy and safety of prednisone, cyclophosphamide, doxorubicin and carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy', in Clinical Lymphoma Myeloma and Leukemia, Elsevier BV, Vol. 23, pp. S196 - S196, http://dx.doi.org/10.1016/s2152-2650(23)01907-9

Conference Papers | 2023

Li E; Bryant C; Jones E; King T; Talaulikar D; Ng J; Bryant A; Ridha Z; Doo NW; Ling S; Ho PJ; Joshua D, 2023, 'The efficacy and safety of prednisone, cyclophosphamide, doxorubicin and carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy', in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, CIG MEDIA GROUP, LP, pp. S196 - S196

Conference Abstracts | 2023

Marivel A-MJ; Roberts TL; Descallar J; Aung WPP; Cheng J; Becker TM; James A; Ma Y; Bryant A; Ling S, 2023, 'Multiple Myeloma in the Culturally and Linguistically Diverse Southwestern Sydney, Australia', in BLOOD, ELSEVIER, CA, San Diego, Vol. 142, presented at 65th Annual Meeting of the American-Society-of-Hematology (ASH), CA, San Diego, 09 December 2023 - 12 December 2023, http://dx.doi.org/10.1182/blood-2023-185193

Conference Abstracts | 2021

Plesner T; Harrison SJ; Quach H; Lee CH; Bryant A; Vangsted AJ; Estell J; Delforge M; Offner F; Twomey P; Choeurng V; Li J; Hendricks R; Sumiyoshi T; Miller K; Choi E; Schjesvold FH, 2021, 'A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)', in BLOOD, ELSEVIER, GA, Atlanta, Vol. 138, presented at 63rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), GA, Atlanta, 11 December 2021 - 14 December 2021, http://dx.doi.org/10.1182/blood-2021-147418

Conference Abstracts | 2020

McCaughan GJ; Tran S; Durrant S; Harrison SJ; Morton J; Horvath N; Spencer A; Kerridge IH; Er JAK; Barge L; Bryant A; Filshie RJ; Choong E; Lai HC; Tiley C; Mills AK; Butler A; Moore J; Hertzberg M; Kennedy GA; Ho PJ; Sidiqi MH; Bashford J; Routledge D; Taylor K; Lee CH; Kalff A; Xia W; Hamad N, 2020, 'Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study', in BLOOD, ELSEVIER, ELECTR NETWORK, Vol. 136, presented at 62nd Annual Meeting of the American-Society-of-Hematology (ASH), ELECTR NETWORK, 05 December 2020 - 08 December 2020, http://dx.doi.org/10.1182/blood-2020-138991

Conference Abstracts | 2020

McCaughan GJ; Verma A; Ling S; Lavee O; Moore J; Bryant A, 2020, 'Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethathasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres', in BLOOD, ELSEVIER, ELECTR NETWORK, Vol. 136, presented at 62nd Annual Meeting of the American-Society-of-Hematology (ASH), ELECTR NETWORK, 05 December 2020 - 08 December 2020, http://dx.doi.org/10.1182/blood-2020-139269

Conference Abstracts | 2019

Haack R; Mallik S; Sungala N; Bryant A; Ho LL; Motum P, 2019, 'COPPER DEFICIENCY: DON'T YOU FORGET ABOUT ME.', in INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, WILEY, Vol. 41, pp. 68 - 68, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000487566000106&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2016

Watson A-M; Bryant A; Davison S; Ling S; Levy M, 2016, 'Treatment of Otherwise Ineligible Donors for Hepatitis B Prior to Matched Sibling Allogeneic Stem Cell Transplant', in BONE MARROW TRANSPLANTATION, SPRINGERNATURE, SPAIN, Valencia, Vol. 51, pp. S140 - S140, presented at 42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, SPAIN, Valencia, 03 April 2016 - 06 April 2016

Conference Abstracts | 2013

Bryant A; Kershaw G; Zebeljan D; Motum P; Das R, 2013, 'Factor VIII inhibitor and pulmonary embolism developing in a patient after meningioma resection: clinical and laboratory aspects', in JOURNAL OF THROMBOSIS AND HAEMOSTASIS, WILEY-BLACKWELL, Vol. 11, pp. 1021 - 1021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000331833604400&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2013

Dalal BI; Al Mugairi A; Bryant A; Lau S; Pi S; Khare NS; Pal J; Abou Mourad Y, 2013, 'Aberrant Expression of Myeloid Antigens Identifies a Subgroup of Standard-Risk Adult Acute Lymphoblastic Leukemia Patients with Short Survival', in BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, ELSEVIER SCIENCE INC, UT, Salt Lake City, Vol. 19, pp. S223 - S224, presented at BMT Tandem Meetings, UT, Salt Lake City, 13 February 2013 - 17 February 2013, http://dx.doi.org/10.1016/j.bbmt.2012.11.268

Conference Abstracts | 2011

Bryant AJ; Palma CA; Lutherborrow M; Jayaswal V; Yang YH; Ma D, 2011, 'Knockdown of MicroRNA-10a in Acute Myeloid Leukaemia Cells Bearing the Nucleophosmin1 Mutation Causes Cell Death and Reduced Clonogenicity', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, Vol. 118, pp. 599 - 600, presented at 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, CA, San Diego, 10 December 2011 - 13 December 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000299597101636&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2011

Bryant AJ; Pillai E; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil SS; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearling R; Nivison-Smith I; Moore J, 2011, 'A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998-2008', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, Vol. 118, pp. 1772 - 1772, presented at 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, CA, San Diego, 10 December 2011 - 13 December 2011

Conference Abstracts | 2011

Bryant AJ; Pillai E; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil SS; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearling R; Nivison-Smith I; Moore J, 2011, 'A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998–2008,', in Blood, American Society of Hematology, Vol. 118, pp. 4143 - 4143, http://dx.doi.org/10.1182/blood.v118.21.4143.4143

Conference Papers | 2011

Palma CA; Tonna E; Bryaht AJ; Jayaswal V; Agapiou D; Yang YH; Ma D; Lutherborrow M, 2011, 'MicroRNA Expression in Acute Myeloid Leukaemia and Their Effects on the Differentiation of Acute Myeloid Leukaemia Cells', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, pp. 1044 - 1044, presented at 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, CA, San Diego, 10 December 2011 - 13 December 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000299597103296&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts | 2011

Palma CA; Tonna E; Bryant AJ; Jayaswal V; Agapiou D; Yang YH; Ma D; Lutherborrow M, 2011, 'MicroRNA Expression in Acute Myeloid Leukaemia and Their Effects on the Differentiation of Acute Myeloid Leukaemia Cells', in Blood, American Society of Hematology, Vol. 118, pp. 2430 - 2430, http://dx.doi.org/10.1182/blood.v118.21.2430.2430

Conference Abstracts | 2007

Bryant A; Moore JJ; Dodds AJ; Milliken ST; Fay K; Ma DD, 2007, 'Pneumonitis and renal toxicity with sirolimus based GVHD prophylaxis for RIC allogeneic', in Haematologica - the Hematology Journal, Ferrata Storti Foundation, Vol. 92, pp. 516 - 516

Please contact my unit using the email below for further information about active clinical trials at Liverpool and SWSLHD

Follow

Dr Adam Bryant

Follow me